Trials / Completed
CompletedNCT01037023
Regulatory Hycamtin(Oral) PMS
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 92 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
Detailed description
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information Topotecan will be administered as described the prescribing information or by physician's decision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topotecan | patients administrated Topotecan according to the prescribing information |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2009-12-21
- Last updated
- 2015-04-15
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01037023. Inclusion in this directory is not an endorsement.